Matrix Metalloproteinase (MMP)-8 and Tissue Inhibitor of MMP-1 (TIMP-1) Gene Polymorphisms in Generalized Aggressive Periodontitis: Gingival Crevicular Fluid MMP-8 and TIMP-1 Levels and Outcome of Periodontal Therapy

WOS: 000341580100013PubMed ID: 24283658Background: The aim of the present study is to investigate matrix metalloproteinase (MMP)-8 and tissue inhibitor of MMP-1 (TIMP-1) gene polymorphisms in generalized aggressive periodontitis (GAgP) and to assess the effects of MMP-8 and TIMP-1 genotypes on the outcomes of non-surgical periodontal therapy. Methods: Genomic DNA was obtained from peripheral blood of 100 patients with GAgP and 167 periodontally healthy controls. MMP-8 +17 C/G, -799 C/T, -381 A/G and TIMP-1 372 T/C, *429 T/G polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism. Patients with GAgP received non-surgical periodontal therapy and were followed for 6 months. Clinical periodontal parameters and gingival crevicular fluid (GCF) samples were collected at baseline and at follow-up visits. GCF biomarkers were analyzed by immunofluorescence assay and enzyme-linked immunosorbent assay. Results: Distribution of the MMP-8 -799 C/T genotypes was significantly different between the GAgP and control groups (P 0.0125). Conclusion: On the basis of the present findings, it can be suggested that MMP-8 -799 C/T and TIMP-1 372 T/C, *429 T/G gene polymorphisms in males may be associated with the susceptibility to GAgP in the Turkish population.Academy of Finland Helsinki, FinlandAcademy of Finland; Research Foundation of Helsinki University Central Hospital; Ege University Research FoundationEge UniversityThis study was supported by grants from the Academy of Finland Helsinki, Finland, and the Research Foundation of Helsinki University Central Hospital and Ege University Research Foundation. Dr. Sorsa is an inventor of oral fluid diagnostic US patents (5652247, 57336341, 5866432, 6143476). The authors report no conflicts of interest related to this study